학술논문
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study.
Document Type
Article
Author
Source
Subject
*NON-Hodgkin's lymphoma
*GAIN-of-function mutations
*
Language
ISSN
1042-8194
Abstract
Deregulation of normal epigenetic regulatory mechanisms, including histone acetylation, is increasingly recognized as a major driver in lymphoma, particularly germinal center origin non-Hodgkin lymphomas like follicular lymphoma (FL) and the germinal center subtype of diffuse large B-cell lymphoma (DLBCL) [[1]]. Six of seven patients had I CREBBP i mutations, and one patient with FL had an I EP300 i mutation (Supplementary Figure 1). In patients with FL, FLIPI scores were 0-1 in two patients, 2 (moderate risk) in one patient, and 3-5 (high risk) in two patients. [Extracted from the article]